|
|
| | PB-22-d9 Basic information |
| Product Name: | PB-22-d9 | | Synonyms: | PB-22-d9;1-pentyl-2,2',3,3',4,4',5,5,5-d9-8-quinolinylester-1H-indole-3-carboxylicacid | | CAS: | 2484977-00-4 | | MF: | C23H13D9N2O2 | | MW: | 367.488436002 | | EINECS: | | | Product Categories: | | | Mol File: | 2484977-00-4.mol |  |
| | PB-22-d9 Chemical Properties |
| solubility | DMF: 11 mg/ml
DMF: PBS (pH 7.2) (1:2): 0.33 mg/ml
DMSO: 10 mg/ml |
| | PB-22-d9 Usage And Synthesis |
| Description | PB-22-d9 (exempt preparation) (Item No. 22871) is intended for use as an internal standard for the quantification of PB-22 (Item No. ISO00122) by GC- or LC-MS. PB-22 is categorized as a synthetic cannabinoid.1 It mimics the effects of Δ9-THC (Item Nos. 12068 | ISO60157). PB-22 is regulated as a Schedule I compound in the United States. PB-22-d9 (exempt preparation) (Item No. 22871) is provided as a DEA exempt preparation. This product is intended for research and forensic applications.WARNING This product is not for human or veterinary use. | | References | [1] SAMUEL D. BANISTER. Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135[J]. ACS Chemical Neuroscience, 2015, 6 8: 1445-1458. DOI: 10.1021/acschemneuro.5b00107 |
| | PB-22-d9 Preparation Products And Raw materials |
|